Summary & Overview
CPT 36512: Apheresis for Removal of Red Blood Cells
CPT code 36512 represents therapeutic apheresis specifically performed for the removal of red blood cells. As a targeted blood-component removal procedure, it is clinically important for managing conditions where reduction of red cell mass is indicated and is performed in specialized hospital or infusion settings. Nationally, accurate coding for this procedure affects clinical reporting, utilization tracking, and payer reimbursement across major public and private payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for CPT code 36512, typical sites of service, and the common modifiers used with apheresis claims. The publication presents benchmarking metrics and payment policy considerations relevant to national payers, highlights documentation elements that support medical necessity for red blood cell apheresis, and summarizes typical billing practices. This resource is intended for billing professionals, clinical coders, and policy analysts who need a clear, national-level summary of how CPT code 36512 is described, where it is performed, and what stakeholders commonly consider when processing claims.
Billing Code Overview
CPT code 36512 describes apheresis for removal of red blood cells, a therapeutic procedure that uses specialized equipment to separate and remove selected blood constituents from whole blood while retransfusing the remainder to the patient. The procedure is reported specifically for the removal of red blood cells.
Service Type: Therapeutic apheresis (red blood cell removal)
Typical Site of Service: Hospital inpatient or outpatient apheresis unit, specialized infusion center, or transfusion service
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 48-year-old patient with severe autoimmune hemolytic anemia presents with rapid hemoglobin decline and symptomatic anemia unresponsive to corticosteroids. The hematology team determines urgent red blood cell (RBC) apheresis is indicated to remove circulating pathogenic red cells and reduce hemolysis while immunosuppressive therapy is optimized. The patient is admitted to an inpatient hematology unit or treated in an outpatient apheresis suite staffed by an apheresis-trained physician and certified apheresis nurse. Vascular access is obtained via a central venous catheter or large-bore peripheral IV depending on access quality. Baseline vitals, complete blood count, coagulation studies, and type and crossmatch are performed. The apheresis machine is programmed for RBC exchange/pheresis parameters and anticoagulation (typically citrate or heparin), and monitored throughout the procedure for hemodynamic stability, citrate toxicity, and bleeding. Post-procedure, the patient is observed for access complications and clinical response; laboratory tests are repeated to document hemoglobin and hemolysis marker changes and guide additional treatments.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
23 | Unusual anesthesia | Use when medically necessary general anesthesia is provided for an otherwise non‑anesthetized therapeutic apheresis procedure due to patient condition. |